ReviewFrontiers in immunology2020
NLRP3 Inflammasome: The Stormy Link Between Obesity and COVID-19.
Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it, 94 citations in OpenAlex.
- The effect of colchicine on mortality outcome and duration of hospital stay in patients with COVID-19: A meta-analysis of randomized trials.Immunity, inflammation and disease · 2022Pooled it
- Hidden Hunger in Pediatric Obesity: Redefining Malnutrition Through Macronutrient Quality and Micronutrient Deficiency.Nutrients · 2025Review
- Cellular Immunity in Obesity: Pathophysiological Insights and the Impact of Bariatric Surgery.International journal of molecular sciences · 2025Review
- Factors affecting COVID-19 outcomes in Ireland: findings from a national database of 1,408,249 cases diagnosed between 2020 and 2022.BMC public health · 2025Article
- The Role of ACE2 Receptor and Its Polymorphisms in COVID-19 Infection and Severity and Its Association with Lipid Profile, Thrombin, and D-Dimer Levels in Iraqi Patients: A Cross-Sectional Study.Biochemical genetics · 2025Article
- Review
- COVID-19 Induces Greater NLRP3 Inflammasome Activation in Obese Patients than Other Chronic Illnesses: A Case-Control Study.International journal of molecular sciences · 2025Article
- Facing stress and inflammation: From the cell to the planet.World journal of experimental medicine · 2024Review
- Body Mass Index and Postacute Sequelae of SARS-CoV-2 Infection in Children and Young Adults.JAMA network open · 2024Article
- NLRP3 inflammasome: a key player in the pathogenesis of life-style disorders.Experimental & molecular medicine · 2024Review
- The fatal contribution of serine protease-related genetic variants to COVID-19 outcomes.Frontiers in immunology · 2024Article
- Bioinformatics and system biology approach to identify potential common pathogenesis for COVID-19 infection and osteoarthritis.Scientific reports · 2023Article
- Article
- High-dose intravenous anakinra treatment is safe and effective in severe and critical COVID-19 patients: a propensity score-matched study in a single center.Inflammopharmacology · 2023Observational
- Cell death and inflammation during obesity: "Know my methods, WAT(son)".Cell death and differentiation · 2023Review
- Risks and burdens of incident dyslipidaemia in long COVID: a cohort study.The lancet. Diabetes & endocrinology · 2023Article
- Links between COVID-19 and Parkinson's disease/Alzheimer's disease: reciprocal impacts, medical care strategies and underlying mechanisms.Translational neurodegeneration · 2023Review
- Herbal medicine for the treatment of obesity-associated asthma: a comprehensive review.Frontiers in pharmacology · 2023Review
- A shared genetic contribution to osteoarthritis and COVID-19 outcomes: a large-scale genome-wide cross-trait analysis.Frontiers in immunology · 2023Article
- Alcohol use disorder as a potential risk factor for COVID-19 severity: A narrative review.Alcoholism, clinical and experimental research · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several countries around the world have faced an important obesity challenge for the past four decades as the result of an obesogenic environment. This disease has a multifactorial origin and it is associated with multiple comorbidities including type 2 diabetes, hypertension, osteoarthritis, metabolic syndrome, cancer, and dyslipidemia. With regard to dyslipidemia, hypertriglyceridemia is a well-known activator of the NLRP3 inflammasome, triggering adipokines and cytokines secretion which in addition induce a systemic inflammatory state that provides an adequate scenario for infections, particularly those mediated by viruses such as HIV, H1N1 influenza, and SARS-CoV-2. The SARS-CoV-2 infection causes the coronavirus disease 2019 (COVID-19) and it is responsible for the pandemic that we are currently living. COVID-19 causes an aggressive immune response known as cytokine release syndrome or cytokine storm that causes multiorgan failure and in most cases leads to death. In the present work, we aimed to review the molecular mechanisms by which obesity-associated systemic inflammation could cause a more severe clinical presentation of COVID-19. The SARS-CoV-2 infection could potentiate or accelerate the pre-existing systemic inflammatory state of individuals with obesity,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.